Drug research

SPN-817

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as (-)-Huperzine A extended-release

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyNCT05518578	SUPN	Phase 2	Recruiting	2027-12-31Estimated
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresNCT06798896	SUPN	Phase 2	Recruiting	2027-08Estimated
SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresNCT07141329	SUPN	Phase 2	Recruiting	2027-12-31Estimated

SUPNRecruitingPrimary completion: 2027-12-31 · Estimated

Trial details

SUPNRecruitingPrimary completion: 2027-08 · Estimated

Trial details

SUPNRecruitingPrimary completion: 2027-12-31 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.